SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense community debate, with bulls citing institutional adoption and potential legislative catalysts, while bears point to cooling ETF demand and geopolitical tensions as signals of a deepening correction. The community remains sharply divided between those viewing current price action as a strategic accumulation phase and others warning that a failure to hold key support levels could trigger a broader downside move.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing a surge in community interest following reports of significant stock purchases by Donald Trump, fueling speculation about its role as a key enterprise AI partner alongside major tech leaders. Traders are actively debating whether this movement represents a sustainable rotation out of semiconductor stocks into high-quality software, despite ongoing volatility and mixed sentiment regarding the stock's recent performance.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently under the microscope as market participants weigh the potential impact of the upcoming Senate Banking Committee markup of the CLARITY Act. While institutional interest remains highhighlighted by major firms launching tokenized funds on the networkcommunity sentiment is divided between optimism for regulatory breakthroughs and frustration over recent price consolidation.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending following the U.S. Senate Banking Committee's 15-9 vote to advance the Clarity Act, sparking intense community debate over whether this regulatory milestone marks a long-awaited catalyst for institutional adoption or another cycle of hype-driven price manipulation. While bulls view the committee approval as a critical step toward legal certainty for the ledger, skeptics remain vocal about the bill's remaining legislative hurdles and express frustration over the token's limited short-term price movement.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is facing intense retail volatility as investors react to management's decision to slow Ethereum accumulation, fueling a heated debate between those calling for a share buyback and critics labeling the stock a scam. While the community is sharply divided over the company's valuation relative to its NAV, many are shifting their focus to upcoming legislative catalysts, specifically the progress of the Clarity Act, which remains a key point of discussion for the future of crypto-integrated financial assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the announcement of an exclusive supply agreement for the Tokyo-172 BCG strain, a move community members view as a strategic breakthrough to bypass long-standing U.S. supply shortages and bolster the commercial rollout of Anktiva. Investors are currently hyper-focused on this development and the company's aggressive presence at the American Urological Association meeting as potential catalysts to break the stock out of its recent trading range.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is seeing significant trading volume and upward momentum as investors position themselves for the highly anticipated SpaceX IPO and Anthropic's future listing. The community is actively debating the fund's premium over its net asset value while debating whether current price action reflects the strategic value of its private equity holdings.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silver is experiencing heightened volatility and intense community debate as investors weigh the metal's role in AI infrastructure demand against persistent macroeconomic pressures. The discussion is currently polarized between bulls who view recent pullbacks as buying opportunities for a long-term cyclical trend, and bears who argue that cooling industrial demand and shifting bond yields signal the end of the current rally.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors weigh the impact of rising Treasury yields and geopolitical tensions against the sustained AI-driven rally in the semiconductor sector. Community discourse is sharply divided between traders capitalizing on the intense momentum and those anticipating a major correction due to concerns over valuation levels and broader macroeconomic risks.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as investors react to federal intervention invoking the Defense Production Act, which mandates the restart of critical California pipeline infrastructure despite ongoing state-level legal opposition. The community is actively debating the potential for a massive short squeeze and long-term production catalysts, with significant attention on the company's ability to navigate jurisdictional conflicts and finalize commercial oil sales.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stocks To Add to Your Watchlist - May 6th

Danaher, Avalo Therapeutics, Vertex Pharmaceuticals, United Therapeutics, argenex, ImmunityBio, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science and technology t...

Avalo Therapeutics (NASDAQ:AVTX) Reaches New 1-Year High Following Analyst Upgrade

Avalo Therapeutics (NASDAQ:AVTX) Sets New 52-Week High Following Analyst Upgrade...

Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $58.00

BTIG Research upped their target price on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a 'buy' rating in a research report on Wednesday...

<ul class="summary-bullets"><li>Avalo is looking to sell 19.73 million shares at $17.75 each, a 9% premium over Tuesday’s closing price.</li><li>Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, its skin inflammation treatment.</li><li>On Tuesday, Avalo said its Phase 2 trial of Abdakibart met its primary endpoint.</li></ul>Shares of Avalo Therapeutics (AVTX) skyrocketed nearly 45% in pre-market trading on Wednesday, as investors cheered the biotech firm’s latest data from a Phase 2 trial to treat a type of skin inflammation, as well as a capital raise to support its pipeline.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AVTX">AVTX shares</a> would trade at their highest levels in more than two years, while also breaching the key 50-day moving average (50-DMA) for the first time in nearly a month.<h2 class="st-heading-2">Offering Priced At A Premium Over AVTX Stock’s Tuesday Closing Price</h2>Avalo Therapeutics is expected to raise around $375 million via a public offering, selling 19.73 million shares at $17.75 each, along with pre-funded warrants for 1.4 million shares priced at a similar level. This represents a 9% premium over the stock’s closing price on Tuesday.The company also granted underwriters a 30-day option to purchase up to an additional 3.17 million shares on the same terms. The deal is set to close on May 7, 2026.Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, including an upcoming Phase 3 data readout. Remaining funds will support working capital and general corporate needs.<h2 class="st-heading-2">AVTX’s Treatment Meets Primary Endpoint In Phase 2 Study</h2>On Tuesday, Avalo <a href="https://stocktwits.com/news-articles/markets/equity/avtx-surges-after-hours-as-skin-disease-drug-shows-desired-clinical-results/cZQDXbORe9U">reported</a> strong Phase 2 results from its Lotus trial of Abdakibart, an investigational treatment for patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin condition.The study met its primary endpoint, with 75% reductions observed in 42.2% of patients on the 150 mg dose and 42.9% on the 300 mg dose at Week 16, both statistically significant and among the highest reductions reported in similar trials.Abdakibart was well tolerated, with mostly mild to moderate side effects and no unexpected safety issues. Based on these results, Avalo plans to advance the treatment into Phase 3 development.<h2 class="st-heading-2">Retail Pegs $21 As AVTX’s Support</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes on the counter surged 5,900% over a 24-hour period.Chatter focused on the offering, with one user saying the stock could fall from its current levels and settle at $21.<stembedurl>https://stocktwits.com/Alternative1/message/652405013</stembedurl>Another user also saw $21 as a key level, adding that despite the strong fundamentals, the stock price won’t climb to $30 on Wednesday.<stembedurl>https://stocktwits.com/Alternative1/message/652397421</stembedurl>AVTX shares have declined 11% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of stock market chart on a glowing particle world map. (Representative Image: Getty Images)

This Small-Cap Biotech Stock Is Tracking A Crucial Bullish Technical Milestone – And Retail Traders Are Taking Notice

Avalo Therapeutics announced a $375 million capital raise following a positive Phase 2 trial for skin inflammation treatment.

Why Did AVTX Stock Surge 45% In Pre-Market Today?

Equity

Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why

Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375 million offering.read more...

<ul class="summary-bullets"><li>Avalo said it now plans to advance abdakibart into a registrational late-stage program.</li><li>42.5% of patients on the drug experienced a 75% reduction in total abscess and inflammatory nodule (AN) count from baseline at week 16.</li><li>The firm also announced a public offering of common stock and pre-funded warrants to raise funds for the further development of the drug candidate.</li></ul>Shares of Avalo Therapeutics (AVTX) surged more than 50% in after-hours trading on Tuesday after the clinical-stage biotech reported positive topline results from a mid-stage trial of its experimental drug abdakibart in patients with moderate to severe hidradenitis suppurativa (HS).The stock had already closed up roughly 18% in regular trading ahead of the announcement.<h2 class="st-heading-2">Trial Data</h2>Hidradenitis suppurativa (HS) is a chronic, non-contagious inflammatory skin condition causing painful, recurring, and draining lumps (abscesses or boils) in hair-bearing areas. In the trial, Avalo was evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa across two dosing regimens.At both doses, the drug demonstrated improvement, with 42.5% of patients experiencing a 75% reduction in total abscess and inflammatory nodule (AN) count from baseline at week 16, the company said. In comparison, only 25.6% of patients on placebo achieved similar outcomes.The company further noted that abdakibart was well tolerated, with the percentage of subjects with treatment-emergent adverse events similar across abdakibart treatment arms and placebo. Avalo said it now plans to advance abdakibart into a registrational late-stage program.Separately, Avalo announced a proposed public offering of common stock and pre-funded warrants. It did not disclose the size of the offering. The company said it intends to use the net proceeds, together with existing cash, to advance the clinical development of abdakibart, and for working capital and other general corporate purposes.<h2 class="st-heading-2">How Did AVTX Retail Traders React?&nbsp;</h2>On Stocktwits, retail sentiment around AVTX stock jumped from ‘bearish’ to ‘bullish’ territory while message volume increased from ‘low’ to ‘high’ levels.A Stocktwits user called for people to exit their position in light of upcoming dilution.<stembedurl>https://www.stocktwits.com/Thsuke7/message/652363602</stembedurl>Another user opined that the rally seems overextended.<stembedurl>https://www.stocktwits.com/TrdrEG/message/652361859</stembedurl><a href="https://stocktwits.com/symbol/AVTX">AVTX stock</a> has gained 224% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/zim-shares-spike-as-rival-4.5-billion-buyout-proposal-trumps-german-deal/cZQDaccRe9D">ZIM Shares Spike As Rival $4.5B Buyout Proposal Trumps German Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Parsons Corp rose premarket on Tuesday(Representative image: Getty Images)

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results 

Avalo was evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa across two dosing regimens.

Avalo Therapeutics (AVTX) to Release Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-avalo-therapeutics-inc-stock...

Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,457 shares of the company's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the...

Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the...

Moody Aldrich Partners LLC Buys Shares of 133,231 Avalo Therapeutics, Inc. $AVTX

Moody Aldrich Partners LLC bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 133,231 shares of the c...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVTX News

AVTXAvalo Therapeutics Inc